Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ankyra

Request full access

Developing a platform to significantly improve both the safety and efficacy of cytokine immunotherapies for cancer

Cambridge, United StatesFounded 2019Biotech & Life Sciences

About Ankyra

Ankyra Therapeutics is a biotechnology startup that is developing a platform to enhance the safety and effectiveness of cytokine immunotherapies for cancer treatment. Cytokine immunotherapies are powerful immune stimulants used to treat cancer, but their use is often limited due to broad immune activation and toxicity. Ankyra's innovative approach involves localizing cytokines specifically and persistently in tumor tissue, creating intense inflammation hot spots that trigger an anti-tumor immune response. This method is being developed for the treatment of solid tumors.

The company's business model revolves around research and development, with a focus on creating innovative solutions for cancer treatment. Ankyra operates in the biotechnology and healthcare market, serving clients such as hospitals, healthcare providers, and potentially patients suffering from cancer. The company generates revenue through the development and commercialization of its cytokine immunotherapy platform.

Ankyra is led by a team of experienced professionals and scientists, including co-founder and chairman Dr. Tillman Gerngross, and President and CEO Dr. Howard L. Kaufman. The company's scientific advisory board comprises esteemed professionals from institutions such as Harvard Medical School, National Cancer Institute, and the Koch Institute for Integrative Cancer Research at MIT.

In summary, Ankyra Therapeutics is a promising startup in the biotechnology sector, developing innovative solutions to improve cancer treatment. Its unique approach to cytokine immunotherapy could potentially revolutionize the way solid tumors are treated, providing a safer and more effective alternative to current methods.

Source: Dealroom company data

At a glance

Status
Operational
Employees
25
Open positions
1
Dealroom signal
80.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Sep 2021 $45M $180M Polaris Partners · Fidelity Investments · Borealis Ventures · Spring Mountain Capital —
EARLY VCOther financing May 2020 $15M $58M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Ankyra website traffic

Latest recorded traffic for Ankyra is 900 monthly website visits, down 50% over the last three months. Ankyra's team grew 0% over the past year.

Latest monthly visits900 3-month web change-50% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Ankyra in the Cambridge ecosystem

Live from Dealroom

The Ankyra office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

Other known investors1 additional known investor

  • Massachusetts Institute of Technology
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ankyra on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ankyra’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.